Table 1.

Demographics, clinical characteristics, visual ratings of medial temporal lobe and posterior atrophy and APOE genotypes of all patients.

Patient group	tAD	PCA1	PCA2	Pairwise comparisona
N	18	16	5	PCA2 vs PCA1	PCA2 vs tAD
Symptom onset	Memory	Vision	Posterior non-vision
Gender (%female)	11 (61%)	9 (56%)	3 (60%)	0.64b	1.00b
Disease duration	4.4 ± 2.5	4.2 ± 2.9	3.6 ± 1.3	0.86	0.70
Age at assessment	60.1 ± 4.8	63.1 ± 5.3	62 ± 5.9	0.70c	0.54c
MMSE	18 ± 4.8 (11–28)	15 ± 3.5 (10–21)	18 ± 5.8 (9–23)	0.25c	0.78c
MTAd	0.8 ± 0.9	1.1 ± 0.9	1.5 ± 1.0	0.74	0.20
	1 (0–3)	1 (0–4)	1 (0–3)
PAd	2.0 ± 1.0	2.3 ± 0.7	2.3 ± 0.8	0.95	0.52
	2 (0–3)	2 (1–3)	2.5 (1–3)
APOE ε2/ε3 (%)e	2 (14%)
APOE ε3/ε3 (%)	4 (28%)	9 (60%)	2 (40%)	0.63b	0.58b
APOE ε4/ε3 (%)	5 (35%)	6 (40%)	3 (60%)	0.59b	0.31b
APOE ε4/ε4 (%)	3 (21%)

Data presented as N (%), median (range) or mean (SD). Abbreviations: MTA, medial temporal atrophy visual rating scale; PA, posterior atrophy visual rating scale.

^aMann-Whitney U test (except indicated).

^bFisher exact test.

^cUnpaired t-test.

^dMR available for 30 individuals: 9 tAD, 16 PCA1, 5 PCA2.

^eAPOE available for 34 individuals: 14 tAD, 15 PCA1, 5 PCA2.